Measurable Residual <i>FLT3-ITD</i> before Allogeneic Transplant for Acute Myeloid Leukemia
Laura W. Dillon(Institute of Cancer Research), Christopher S. Hourigan(National Heart Lung and Blood Institute), Kristin Page(Medical College of Wisconsin), Antonio Jiménez(University of Miami), Zoë C. Wong(National Institutes of Health), Marcos de Lima(The Ohio State University), Devdeep Mukherjee(National Institutes of Health), Firas El Chaer(The University of Texas MD Anderson Cancer Center), Jeffrey E. Miller(MesoScribe Technologies (United States)), Georgia Andrew(National Institutes of Health), Gege Gui(Johns Hopkins University), Wael Saber(Medical College of Wisconsin), Stephen R. Spellman(National Marrow Donor Program), Partow Kebriaei(The University of Texas MD Anderson Cancer Center), Matthew J. Holman(Center for Astrophysics Harvard & Smithsonian), Mark R. Litzow(Mayo Clinic in Arizona), Jeffery J. Auletta(Nationwide Children's Hospital), Ying Huang(MesoScribe Technologies (United States)), Niveditha Ravindra(National Institutes of Health), Jason Gerhold(MesoScribe Technologies (United States)), Steven M. Devine(National Marrow Donor Program)
Cited by 1
Related Papers
Kepler Planet-Detection Mission: Introduction and First Results
|Science|2010|4.1k
Transiting Exoplanet Survey Satellite
|Journal of Astronomical Telescopes Instruments and Systems|2014|4.1k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k